-
Long-standing barriers complicate patient care despite effective DKD treatment options
Maryam Afkarian, MD, PhD, will explore some of the challenges to the practical application of tools to manage diabetes and kidney disease.
-
Experts to weigh starting SGLT2 inhibitors and GLP-1 receptor agonists in the hospital
Jennifer Green, MD, will discuss some of the factors that may give clinicians second thoughts about initiating the two drug classes.
-
High dimensional data moves from bench to bedside with focus on individualized care
Manoj Bhasin, PhD, MS, will unveil some of the latest developments in multi-dimensional and spatial single-cell omics.
-
81st Scientific Sessions will showcase the latest basic, translational, and clinical science
Dana Dabelea, MD, PhD, Chair of the 81st Scientific Sessions Meeting Planning Committee, gives an overview of the science and opportunities for live interaction at this year’s virtual meeting taking place June 25–29.
-
Results from head-to-head trial of four type 2 diabetes agents to be presented
“We hope to give a comprehensive, comparative view of which drugs do what and in which people,” said GRADE Principal Investigator David Nathan, MD.
-
SURPASS clinical trials may lead to the next chapter in incretin-based therapies
New, detailed results of the first Phase 3 SURPASS clinical trials involving tirzepatide will be presented in a dedicated symposium. “The glucose-lowering and weight reductions of this dual incretin receptor agonist are unprecedented,” said Julio Rosenstock, MD.
-
Popular review session will summarize year of diabetes advances
The session offers a broad look at advancements in basic, clinical, and translational sciences, putting into context recent research and the future of the field. Speakers include Maureen Gannon, PhD, and Jay S. Skyler, MD, MACP.
-
New agents poised to transform management of heart failure
Michelle M. Kittleson, MD, PhD, and Nasrien E. Ibrahim, MD, will discuss how recent trial results can be leveraged to save lives with angiotensin receptor-neprilysin inhibition and SGLT2 inhibitors.
-
Experts will discuss strategies to minimize COVID-19 risks for diabetes patients
The 2021 Diabetes Care Symposium, featuring speakers Matthew C. Riddle, MD, and Paresh Dandona, MD, PhD, will examine how to mitigate the threefold risk for severe COVID-19 infection among diabetes patients.
-
New opportunities to engage at the 81st Scientific Sessions
This year’s Scientific Sessions will incorporate expanded opportunities for attendees to interact with speakers, exhibitors, and one another, explains Robert Gabbay, MD, PhD, ADA Chief Scientific and Medical Officer. Register today to join the live discussions June 25–29!